标题:Pemetrexed for primary central nervous system lymphoma in the elderly
作者:Han, S.; Wang, M.; Liu, B.; Yu, J.
作者机构:[Han, S.; Liu, B.; Yu, J.] Shandong Univ, Shandong Canc Hosp & Inst, Dept Oncol, 440 Jiyan Rd, Jinan 250117, Shandong, Peoples R China.; [Wang, M.] 更多
通讯作者:Yu, J
通讯作者地址:[Yu, J]Shandong Univ, Shandong Canc Hosp & Inst, Dept Oncol, 440 Jiyan Rd, Jinan 250117, Shandong, Peoples R China.
来源:CLINICAL & TRANSLATIONAL ONCOLOGY
出版年:2016
卷:18
期:2
页码:138-143
DOI:10.1007/s12094-015-1345-4
关键词:Chemotherapy; Elderly; Primary central nervous system lymphoma;; Pemetrexed
摘要:The aim of this study was to evaluate the efficacy and safety of a consecutive series of elderly patients with primary central nervous system lymphoma (PCNSL) treated with single-agent pemetrexed without radiotherapy or intrathecal chemotherapy.; Twelve histologically confirmed newly diagnosed PCNSL patients older than 65 years were studied between 2008 and 2013. An induction chemotherapy was initially given (pemetrexed 600 mg/m(2) on day 1, every 3 weeks). Patients achieving a complete, partial response or stable disease proceeded to a maintenance phase (up to 6 cycles). Patients with progressive/recurrent disease (PD) were treated with whole brain radiotherapy on an individual basis.; Four patients presented complete response, six patients showed partial response and two patients presented progressive disease. The median progression-free survival (PFS) was 9.0 months [95 % confidence interval (CI) 2.0-45.3] and the median overall survival was 19.5 months (95 % CI 5.0-45.3). Adverse events included leukocytopenia, anemia, fatigue, rash and vomiting. No neurotoxicity or treatment-related death was observed. The estimated 1-year and 2-year survival rate was 66.7 and 41.7 %, respectively.; Our efficacy results demonstrate that the single-agent pemetrexed was feasible, active and well tolerated in elderly patients with PCNSL. Furthermore, this single-agent regimen results in higher response rates and less toxicity comparable with other chemotherapy or radiotherapy regimens. Prospectively, controlled studies are warranted to confirm such results.
收录类别:SCOPUS;SCIE
WOS核心被引频次:3
Scopus被引频次:3
资源类型:期刊论文
原文链接:https://www.scopus.com/inward/record.uri?eid=2-s2.0-84955563459&doi=10.1007%2fs12094-015-1345-4&partnerID=40&md5=d4e9cb8f70e5e691b636ff47eec2d3c6
TOP